

Accepted Manuscript

Title: Transplant Decisions in Patients with Myelofibrosis: Should Mutations be the Judge?

Author: Rachel B. Salit, H. Joachim Deeg

PII: S1083-8791(17)30806-6

DOI: <https://doi.org/10.1016/j.bbmt.2017.10.037>

Reference: YBBMT 54851


To appear in: *Biology of Blood and Marrow Transplantation*

Received date: 11-10-2017

Accepted date: 26-10-2017

Please cite this article as: Rachel B. Salit, H. Joachim Deeg, Transplant Decisions in Patients with Myelofibrosis: Should Mutations be the Judge?, *Biology of Blood and Marrow Transplantation* (2017), <https://doi.org/10.1016/j.bbmt.2017.10.037>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Transplant Decisions in Patients With Myelofibrosis: Should Mutations Be The Judge?

Rachel B. Salit and H. Joachim Deeg

Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA

Correspondence: H. Joachim Deeg MD

Fred Hutchinson Cancer Research Center

1100 Fairview Avenue North, D1-100

Seattle, WA 98109

jdeeg@fhcrc.org

Keywords: Myeloproliferative neoplasms, myelofibrosis, DIPSS/DIPSS plus, somatic mutations, transplant indications, prognosis

Download English Version:

<https://daneshyari.com/en/article/8429951>

Download Persian Version:

<https://daneshyari.com/article/8429951>

[Daneshyari.com](https://daneshyari.com)